Eli Lilly and Company (LLY) Stock Price Prediction

Target vs 52-Week Range

Eli Lilly and Company is a leading American multinational pharmaceutical company with a market capitalization exceeding $1 trillion. The company is a dominant force in the diabetes and obesity treatment markets, primarily driven by its blockbuster drugs Mounjaro and Zepbound. Beyond its current successes, Eli Lilly is actively expanding its pipeline through significant research and development efforts and strategic acquisitions, focusing on areas such as oncology, neuroscience, immunology, and next-generation cardiometabolic therapies to ensure sustained growth well into the 2030s. Despite trading at a premium valuation, analysts largely maintain a positive outlook, citing the company's robust product pipeline and strong financial performance.

The technical outlook for LLY presents mixed signals. The stock's Relative Strength Index (RSI) is currently at 42.5, indicating neutral conditions, suggesting it is neither overbought nor oversold. However, the Moving Average Convergence Divergence (MACD) line is below the signal line, which typically suggests bearish momentum in the short term. On a more positive note, a 'golden cross' has occurred, with the 50-day moving average positioned above the 200-day moving average, generally considered a bullish long-term indicator. While some shorter-term simple moving averages (8-day, 20-day, 50-day) indicate 'Sell' signals, the 200-day simple moving average provides a 'Buy' signal. The stock has also recently broken through the floor of a rising trend channel in the medium term, potentially signaling a slower rate of ascent or a more horizontal price movement.

The AI price target for Eli Lilly and Company is $1,330.00. This target is supported by highly positive analyst sentiment following the company's exceptional second-quarter 2026 earnings, where it significantly beat both EPS and revenue expectations. Analysts are projecting substantial earnings growth for next year, with an expected increase of 26.19%, from $36.35 to $45.87 per share. The next key event for Eli Lilly will be its third-quarter 2026 earnings report, estimated for October 29, 2026, with a consensus EPS forecast ranging from $9.81 to $9.85. Continued strong performance of key products, such as Mounjaro and Zepbound, could further influence future outlook. Investors should be aware that price targets are estimates and actual market performance can vary.